Out of 8,267 EMS encounters for MDMA-related overdoses from January 1, 2024 to August 31, 2025, 1,655 (20.0%) occurred in Western states, 1,307 (15.8%) in Midwestern states, 4,359 (52.8%) in Southern states and 946 (11.4%) in Northeastern states. The data shows an initial statistically significant decrease in EMS encounters for MDMA-related overdoses, followed by a statistically significant increase across Western, Northeastern and Southern states, and nationally overall. In contrast, Midwestern states experienced the opposite trend.

To view the entire Special Report from our Weekly Briefing, click here.

Click here to learn more about NDEWS Hotspot Alerts

Search Methodology: 266 targeted searches on Reddit were conducted to analyze discussions about high-dose MDMA consumption patterns and associated risks. 159 ended up yielding results pertaining to high dosage MDMA.

Why are we reporting on this? Recent research demonstrates that high-dose MDMA tablets containing 200mg or more are increasingly circulating, with some tablets containing 270-340mg identified internationally. These doses are nearly twice the median dose in Australia and significantly exceed the 80-120mg common dose range.

What is High-Dose MDMA Use? High-dose MDMA use refers to consumption patterns exceeding typical recreational doses of 75-150mg. Reddit users report taking 300-600mg as increasingly common, with some describing "heroic doses" exceeding 1 gram.

Public Health Impacts: Discussants report seizure-like symptoms, loss of consciousness, severe hyperthermia, and hallucinations requiring emergency medical intervention. Reddit commentors describe persistent effects lasting months including depression, anxiety, depersonalization, cognitive impairment. Multiple posts describe users developing panic disorders and PTSD-like symptoms following high-dose experiences.

How is it Being Discussed? Reddit commenters frequently seek validation and reassurance immediately after taking excessive doses, often expressing regret and fear about potential brain damage. Discussants share experiences of losing control during sessions, taking entire supplies of MDMA despite intentions to moderate use. Reddit posters debate whether recovery from high-dose neurotoxicity is possible, with some reporting persistent symptoms years after cessation. The community frequently emphasizes the "3-month rule" between uses, though many admit to violating this guideline. Harm reduction advice is commonly shared, including recommendations for supplements like NAC (N-acetylcysteine) and an emphasis on proper hydration and temperature regulation.

Click here to read more about NDEWS Online Monitoring.

The Rapid Street Reporting (RSR) team visited Cleveland, Ohio between August 8th and 10th, 2025 and surveyed 349 individuals. After alcohol and marijuana for recreational use, the next most commonly reported substances used in the past 12 months were marijuana for medical use (10.0%), psilocybin (9.7%), delta-8 (7.7%), delta-10 (6.6%) and powder cocaine (6.0%). Click here to read the full report.

Click here to read more about NDEWS Rapid Street Reporting.

A recently published comprehensive overview in Disease-a-Month by Farrar et al., co-authored by NDEWS Co-Director Joseph Palamar, highlights MDMA’s psychoactive effects. Additionally, the article addresses the importance of understanding MDMA’s pharmacological properties, interactions with other drugs, and the risks associated with adulteration. Read the full comprehensive overview here.

A recently published study in Forensic Science International by Stelmaszczyk et al. presents the development of a portable sensor system capable of detecting MDMA. The device uses screen-printed carbon electrodes and the square wave voltammetry technique. The system was successfully applied to the analysis of authentic MDMA samples, which affirmed the device as a potentially effective and accessible tool for on-site MDMA detection in forensic settings. Read the full study here.

A recently published study in Drug and Alcohol Dependence led by NDEWS Co-Director Joseph Palamar, in addition to SAG member Alex Krotulski, investigates the prevalence of synthetic cathinones, fentanyl, and xylazine exposure in the New York City nightclub scene in 2024. The study surveyed 1,024 participants and analyzed saliva samples for drug exposure. Results determined that those testing positive for MDMA were more likely to test positive for synthetic cathinones than fentanyl (88.9% vs. 15.4%). The authors concluded that unintentional exposure to synthetic cathinones, fentanyl, and xylazine is occurring through the adulteration of MDMA and other drugs commonly found in the nightclub scene. Read the full study here.

A recently published study in Drug and Alcohol Review by Keygan et al. explores the effects of drug alerts on MDMA use intentions. An online survey was conducted among Australians who used MDMA in the past year, with respondents randomized into an alert or control group. The results indicated that 45.4% of individuals in the alert group reported an intention not to use MDMA, compared to 20.7% in the control group. Additionally, 46.7% of the alert group intended to reduce their initial dose, versus 69.0% in the control group. Read the full study here.

Are you committed to advancing the science of substance use and public health? The University of Florida’s NIDA-funded T32 Training Program offers predoctoral and postdoctoral scholars an exceptional opportunity to launch impactful research careers focused on NDEWS!

What We Offer:
- Interdisciplinary training at the intersection of addiction science, epidemiology, and surveillance
- Mentorship from leading UF faculty in epidemiology, public health, psychology, medicine, and more
- Hands-on research with landmark and important NIH-funded projects and access to rich data
- Career development support, including grant writing, publishing, and professional networking
- A collaborative, inclusive research community committed to reducing the burden of substance use

Eligibility:
- US citizens or permanent residents
- Interested in a PhD in Epidemiology, or early-stage postdoctoral fellows
- Demonstrated interest in substance use, addiction, or public health research

Location: Gainesville, Florida — a dynamic hub for scientific innovation with high quality of life and low cost of living.

📅 Date: Monday, September 29, 2025

🕑 Time: 3:00 pm - 4:00 pm ET

📍 Location: Online 

The NDEWS Weekly Briefing curates emerging data and findings from across the Early Warning Network, which includes three core components: our Scientific Advisory Group (SAG), comprised of national experts and federal partners; our Sentinel Site Directors (SSDs), who lead local surveillance in key geographic regions; and our Community-Based Health Experts, who provide on-the-ground insights from populations most impacted by drug trends. Together, these contributors generate timely, multidisciplinary and impactful information, ranging from peer-reviewed research findings to local surveillance data. These contributions inform public health and research communities.

More about The NDEWS Early Warning Network
- Issue 230: Early Warning in Action — Insights from the NDEWS Early Warning Network
- Issue 234: Early Warning in Action — Insights from the NDEWS Early Warning Network

You can share the NDEWS Weekly Briefing with friends, colleagues, and others who would benefit from information on recent and relevant news, articles, and data related to novel drug trends in the US and globally by clicking here.

Share your research, news, and events through our submission form.

Share your comments on our newsletter through our feedback form.

For more information on NDEWS' efforts, visit our website.

Follow NDEWS on Twitter/X: @NDEWSnews

If you miss or want to learn more about NDEWS Original Content, you can find our archived content on the NDEWS website:

     • NDEWS Hotspot Alerts using substance-related EMS data
     • NDEWS Rapid Street Reporting (RSR) survey data reports
     • NDEWS Web Monitoring Team Reddit Alerts
     • NDEWS Sentinel Site Reports
     • Previous issues of the NDEWS Weekly Briefings

The Weekly Briefing is a newsletter published each week by the National Drug Early Warning System (NDEWS) Coordinating Center, which is funded by the National Institute on Drug Abuse (U01DA051126) to the University of Florida (MPI: Cottler (contact), Co-Is: Goldberger, Nixon, Striley), NYU Langone Health (MPI: Palamar), and Florida Atlantic University (Co-I: Barenholtz). Any item may be reproduced provided the source is acknowledged.